Anavex (AVXL) Life Sciences announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorization Application, MAA, for blarcamesine, ANAVEX 2-73, an investigational drug for the treatment of Alzheimer’s disease. The Company is looking forward to working with the EMA. “The EMA filing acceptance for blarcamesine to review the Marketing Authorization Application potentially brings us a step closer offering broader patient access to a new treatment option in Europe, and we look forward to continued engagement with the EMA,” said Juan Carlos Lopez-Talavera, MD, PhD, Head of Research and Development of Anavex. “Through our clinical development program, we have seen that blarcamesine has the potential to slow the progression of this relentless and ultimately fatal disease.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AVXL:
- Options Volatility and Implied Earnings Moves Today, December 23, 2024
- Options Volatility and Implied Earnings Moves This Week, December 23 – December 26, 2024
- Biotech Alert: Searches spiking for these stocks today
- Anavex announces upcoming presentation of data from ATTENTION-AD study
- Anavex announces submission of blarcamesine MAA to EMA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
